Drug intelligence / Profile preview

ganoderma lucidum spore + enteral nutrition

Development stage: Preclinical
Lead developer: Concord Health Group
Administration: Oral

Overview

This combination involves **ganoderma lucidum spore powder**, which contains active ingredients like polysaccharides, peptides, and triterpenoids, known for their immune-modulating, anti-inflammatory, and antioxidant effects[2]. **Enteral nutrition** provides essential nutrients directly into the gastrointestinal tract, supporting nutritional needs. The combination is studied for its potential to improve quality of life and alleviate symptoms in patients undergoing palliative cancer treatment[1].

Other names: 灵芝孢子粉 + 肠内营养粉剂

Targets

PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on ganoderma lucidum spore + enteral nutrition.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganoderma lucidum spore + enteral nutrition.

Explore the full profile